ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Hypophosphatemic rickets, X-linked dominant
Gene/Gene Panel: PHEX
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2023/05/04
Released (Under revision)
1.2.3
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
PHEX ⇔ 0010619 HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR
Assertion Pending
Assertion Pending
2022/02/09
Released
1.2.3
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
PHEX ⇔ 0010619 HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR
Assertion Pending
Assertion Pending
2022/02/09
Released (Under revision)
1.2.2
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
PHEX ⇔ 0010619 HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR
Assertion Pending
Assertion Pending
2021/12/01
Released
1.2.2
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
PHEX ⇔ 0010619 HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR
Assertion Pending
Assertion Pending
2021/12/01
Released (Under revision)
1.2.1
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
MONDO IDs added
2020/05/02
Released
1.2.1
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
MONDO IDs added
2020/05/02
Released (Under revision)
1.2.0
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.2.0
P
Morbidity of XLHR (rickets, growth, bone/joint pain) (GroupA)
Oral phosphate plus vitamin D analog supplements (GroupA) 9CC
Rickets (GroupA)
Borusumab (GroupA) 9CN
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/23
Released
1.1.1
P
Morbidity of XLHR (rickets, growth, bone/joint pain)
Oral phosphate plus vitamin D analog supplements 9CC
Rickets
Borusumab 9CN
2019/04/23
Released (Under revision)
1.1.0
P
Morbidity of XLHR (rickets, growth, bone/joint pain)
Oral phosphate plus vitamin D analog supplements 9CC
Rickets
Borusumab 9CN
Internal system migration related to merging adult and pediatric contexts.
2019/04/04
Released
1.1.0
P
Morbidity of XLHR (rickets, growth, bone/joint pain)
Oral phosphate plus vitamin D analog supplements 9CC
Rickets
Borusumab 9CN
Internal system migration related to merging adult and pediatric contexts.
2019/02/20
Released
1.0.0
P
Morbidity of XLHR (rickets, growth, bone/joint pain)
Oral phosphate plus vitamin D analog supplements 9CC
Rickets
Borusumab 9CN
2019/02/07
In Preparation
N/A
¤ Powered by BCM's Genboree.